Evaluation of the Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

Also called NCT07714876

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
  • Kardium Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07714876
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07714876. Allocation not applicable; no masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal Atrial Fibrillation
Acronym
PULSAR PAS
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
Globe Pulsed Field System
Lead sponsor
Kardium Inc. (class: industry)

Record details

Record id
cardio:ct-nct07714876
Content hash
a8500c071f939cb7ce20a61b406fc4a0523ace620dbcedb09cbaf03cc70eba91